Osteoporosis Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Osteoporosis pipeline constitutes 30+ key companies continuously working towards developing 35+ Osteoporosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Osteoporosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Osteoporosis Market.

The Osteoporosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Osteoporosis Pipeline Report: https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Osteoporosis treatment therapies with a considerable amount of success over the years.
• Osteoporosis companies working in the treatment market are Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Entera Bio, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others, are developing therapies for the Osteoporosis treatment
• Emerging Osteoporosis therapies in the different phases of clinical trials are- Research programme, RT-102, SHR-1222, EB613, VOLT01, CT-P41, TVB-009, and others are expected to have a significant impact on the Osteoporosis market in the coming years.
• In October 2025, Celltrion, Inc. announced that the U.S. FDA has designated STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable biosimilars to the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications. These interchangeability designations were granted based on comprehensive comparative clinical data including pharmacokinetics, efficacy, safety, and immunogenicity in postmenopausal women with osteoporosis along with analytical evidence demonstrating similarity to the reference products.
• In April 2025, The City of Hope Medical Center has initiated a Phase 1/2 clinical trial investigating whether the osteoporosis drug denosumab can enhance beta cell function in individuals with early type 1 diabetes. Amgen's denosumab is marketed as Prolia for osteoporosis and Xgeva for bone tumors. Additionally, the FDA has approved four sets of biosimilars, the latest being Fresenius's Conexxence/Bomyntra.
• In December 2024, GlycoNex, Inc. (GNX), a clinical-stage biotech company developing glycan-targeted cancer immunotherapies, announced that the first patient has been dosed in the Phase 3 trial of its denosumab biosimilar, SPD8. This pivotal study will evaluate SPD8 for osteoporosis treatment, with unblinded results anticipated in the second quarter of 2026.

Osteoporosis Overview
Osteoporosis is a medical condition characterized by weakened bones that become fragile and more prone to fractures. It occurs when bone density and quality decrease, often due to aging, hormonal changes, or nutritional deficiencies. Commonly affected areas include the hips, spine, and wrists. Early detection, lifestyle modifications, and medications can help strengthen bones, reduce fracture risk, and maintain overall skeletal health.

Get a Free Sample PDF Report to know more about Osteoporosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Osteoporosis Drugs Under Different Phases of Clinical Development Include:
• Research programme: Lactocore
• RT-102: Rani Therapeutics
• SHR-1222: Jiangsu HengRui Medicine
• EB613: Entera Bio
• VOLT01: Levolta Pharmaceuticals, Inc.
• CT-P41: Celltrion
• TVB-009: Teva Pharmaceuticals

Osteoporosis Route of Administration
Osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Osteoporosis Molecule Type
Osteoporosis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Osteoporosis Pipeline Therapeutics Assessment
• Osteoporosis Assessment by Product Type
• Osteoporosis By Stage and Product Type
• Osteoporosis Assessment by Route of Administration
• Osteoporosis By Stage and Route of Administration
• Osteoporosis Assessment by Molecule Type
• Osteoporosis by Stage and Molecule Type

DelveInsight's Osteoporosis Report covers around 35+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Osteoporosis product details are provided in the report. Download the Osteoporosis pipeline report to learn more about the emerging Osteoporosis therapies
https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Osteoporosis Therapeutics Market include:
Key companies developing therapies for Osteoporosis are - Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline PLC, Novartis International AG, Actavis PLC, and others.

Osteoporosis Pipeline Analysis:
The Osteoporosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Osteoporosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoporosis Treatment.
• Osteoporosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Osteoporosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoporosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Osteoporosis drugs and therapies
https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Osteoporosis Pipeline Market Drivers
• Rising geriatric population prone to low bone density, growing investments in research and development, increased Focus on development of biosimilars for the treatment of Osteoporosis are some of the important factors that are fueling the Osteoporosis Market.

Osteoporosis Pipeline Market Barriers
• However, side effects and complications associated with osteoporosis drugs, patent expiration of osteoporosis drugs and other factors are creating obstacles in the Osteoporosis Market growth.

Scope of Osteoporosis Pipeline Drug Insight
• Coverage: Global
• Key Osteoporosis Companies: Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Entera Bio, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others
• Key Osteoporosis Therapies: Research programme, RT-102, SHR-1222, EB613, VOLT01, CT-P41, TVB-009, and others
• Osteoporosis Therapeutic Assessment: Osteoporosis current marketed and Osteoporosis emerging therapies
• Osteoporosis Market Dynamics: Osteoporosis market drivers and Osteoporosis market barriers

Request for Sample PDF Report for Osteoporosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.